Controlled Release of Antiproliferative Drugs From Polymeric Systems for Stent Applications and Local Cancer Treatment
Authors:
- 16 May 2012
- journal article
- review article
- Published by Wiley in Advanced Engineering Materials
- Vol. 14 (6) , B294-B310
Abstract
Restenosis (re‐narrowing of the blood vessel wall) and cancer are two different pathologies that have drawn extensive research attention over the years. Antiproliferative drugs such as paclitaxel inhibit cell proliferation and are therefore effective in the treatment of cancer as well as neointimal hyperplasia, which is known to be the main cause of restenosis. Drug‐eluting stents (DES) significantly reduce the incidence of in‐stent restenosis (ISR), which was once considered a major adverse outcome of percutaneous coronary stent implantations. Localized release of antiproliferative drugs interferes with the pathological proliferation of vascular smooth muscle cells (VSMC), which is the main cause of ISR. Conventional approaches to treating cancer are mainly surgical excision, irradiation, and chemotherapy. In cancer therapy, surgical treatment is usually performed on patients with a resectable carcinoma. An integrated therapeutic approach, such as the addition of a delivery system loaded with an antiproliferative drug at the tumor resection site, is desirable. This will provide a high local concentration of a drug, that is, detrimental to malignant cells which may have survived surgery, thus preventing re‐growth and metastasis of the tumor. The present review describes recent advances in systems for controlled release of antiproliferative agents. It describes basic concepts in drug delivery systems and antiproliferative drugs and then focuses on both types of systems: stents with controlled release of antiproliferative agents, and drug‐eluting particles and implants for local cancer treatment. The last part of this article is dedicated to our novel drug‐eluting composite fiber structures, which can be used as basic stent elements as well as for local cancer treatment.Keywords
This publication has 105 references indexed in Scilit:
- Biodegradable Multiblock Poly[N-(2-hydroxypropyl)methacrylamide] via Reversible Addition−Fragmentation Chain Transfer Polymerization and Click ChemistryMacromolecules, 2011
- Synthesis of biodegradable multiblock copolymers by click coupling of RAFT-generated heterotelechelic polyHPMA conjugatesReactive and Functional Polymers, 2011
- Composite Fiber Structures with Antiproliferative Agents Exhibit Advantageous Drug Delivery and Cell Growth Inhibition In VitroJournal of Pharmaceutical Sciences, 2011
- Postmarket evaluation of breakthrough technologiesAmerican Heart Journal, 2008
- The future of drug-eluting stentsPharmacological Research, 2008
- Four-Year Clinical Follow-Up After Implantation of the Endeavor Zotarolimus-Eluting Stent: ENDEAVOR I, the First-in-Human StudyThe American Journal of Cardiology, 2007
- Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trialActa Neurochirurgica, 2006
- Drug eluting stents in 2005Heart, 2005
- Biodegradable hollow microfibres to produce bioactive scaffoldsPolymer International, 2004
- Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugsSeminars in Cancer Biology, 2004